IMARA Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for rare genetic disorders of hemoglobin. The company has a leading product candidate in IMR-687, which is an oral and once-a-day therapeutic in Phase 2b clinical trials for sickle cell disease and ß-thalassemia. IMARA Inc. also develops IMR-261, an oral activator for nuclear factor erythroid 2-related factor 2 for treating hemoglobinopathies, iron disorders, and other potential areas.